JP2011511622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011511622A5 JP2011511622A5 JP2010541803A JP2010541803A JP2011511622A5 JP 2011511622 A5 JP2011511622 A5 JP 2011511622A5 JP 2010541803 A JP2010541803 A JP 2010541803A JP 2010541803 A JP2010541803 A JP 2010541803A JP 2011511622 A5 JP2011511622 A5 JP 2011511622A5
- Authority
- JP
- Japan
- Prior art keywords
- qpct
- human animal
- mouse
- model
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 claims 12
- 101150035356 Qpct gene Proteins 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 241000699666 Mus <mouse, genus> Species 0.000 claims 8
- 238000010171 animal model Methods 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 238000012216 screening Methods 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 2
- 208000023697 ABri amyloidosis Diseases 0.000 claims 2
- 208000017227 ADan amyloidosis Diseases 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims 2
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 241001323319 Psen Species 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 claims 2
- 238000013279 ApoE knockout mouse model Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108700024394 Exon Proteins 0.000 claims 1
- 208000009386 Experimental Arthritis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 238000006555 catalytic reaction Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000030505 negative regulation of chemotaxis Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035790 physiological processes and functions Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000011552 rat model Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2078408P | 2008-01-14 | 2008-01-14 | |
| PCT/EP2009/050387 WO2009090190A1 (en) | 2008-01-14 | 2009-01-14 | Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011511622A JP2011511622A (ja) | 2011-04-14 |
| JP2011511622A5 true JP2011511622A5 (https=) | 2012-03-01 |
Family
ID=40427980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541803A Pending JP2011511622A (ja) | 2008-01-14 | 2009-01-14 | グルタミニルシクラーゼ遺伝子のノックアウト変異を有するマウスモデル |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9462793B2 (https=) |
| EP (1) | EP2238252B1 (https=) |
| JP (1) | JP2011511622A (https=) |
| AU (1) | AU2009204864A1 (https=) |
| CA (1) | CA2710494A1 (https=) |
| IL (1) | IL206484A0 (https=) |
| NZ (1) | NZ586665A (https=) |
| WO (1) | WO2009090190A1 (https=) |
| ZA (1) | ZA201004367B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3174987B1 (en) | 2014-08-01 | 2023-10-11 | The Johns Hopkins University | Mrgprx2/mrgprb2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| DE122007000007I1 (de) | 1986-04-09 | 2007-05-16 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
| US5602299A (en) | 1992-09-23 | 1997-02-11 | Mount Sinai School Of Medicine Of The City University Of New York | Transgenic animal models for neurodegenerative disease |
| JPH07132033A (ja) | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| US5981830A (en) | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
| US20030013177A1 (en) * | 2001-05-23 | 2003-01-16 | Ebens Allen J. | Polynucleotides encoding insect glutaminyl cyclase and uses thereof |
| US6948038B2 (en) * | 2001-07-24 | 2005-09-20 | Microsoft Corporation | System and method for backing up and restoring data |
| KR20110059664A (ko) | 2003-05-05 | 2011-06-02 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
| JP5690463B2 (ja) | 2003-05-05 | 2015-03-25 | プロビオドルグ エージー | グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用 |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| US8338120B2 (en) | 2003-05-05 | 2012-12-25 | Probiodrug Ag | Method of treating inflammation with glutaminyl cyclase inhibitors |
| JP4806628B2 (ja) | 2003-05-05 | 2011-11-02 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤 |
| BRPI0415409A (pt) | 2003-10-15 | 2006-12-05 | Probiodrug Ag | uso de efetuadores de ciclases de glutaminila e glutamato |
| US20050171112A1 (en) | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| EP2338490A3 (en) | 2003-11-03 | 2012-06-06 | Probiodrug AG | Combinations useful for the treatment of neuronal disorders |
| US7667044B2 (en) | 2003-11-03 | 2010-02-23 | Probiodrug Ag | Compounds for the treatment of neurological disorders |
| US7304086B2 (en) | 2004-02-05 | 2007-12-04 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| BRPI0718507A2 (pt) | 2006-09-21 | 2013-11-12 | Probiodrug Ag | Genes relacionados à glutaminil ciclase |
| JP5599614B2 (ja) | 2006-11-09 | 2014-10-01 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| US8420684B2 (en) | 2006-11-09 | 2013-04-16 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP2010516235A (ja) * | 2007-01-19 | 2010-05-20 | プロビオドルグ エージー | アルツハイマー病及び他のｑｐｃｔ関連障害の治療のためのインビボスクリーニングモデル |
| US7803810B2 (en) | 2007-03-09 | 2010-09-28 | Probiodrug Ag | Inhibitors |
| WO2008128982A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors |
| DK2142515T3 (da) | 2007-04-18 | 2014-06-23 | Probiodrug Ag | Nitrovinyl-diaminderivater som glutaminyl-cyclase-inhibitorer |
| JP5675343B2 (ja) | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としての尿素誘導体 |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| JP5675340B2 (ja) | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | 新規阻害剤 |
| WO2008128983A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Cyano-guanidine derivatives as glutaminyl cyclase inhibitors |
| JP5676249B2 (ja) | 2007-04-20 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体 |
| CA2696934A1 (en) | 2007-09-12 | 2010-02-16 | Probiodrug Ag | Transgenic mice |
-
2009
- 2009-01-14 NZ NZ586665A patent/NZ586665A/en not_active IP Right Cessation
- 2009-01-14 US US12/353,463 patent/US9462793B2/en not_active Expired - Fee Related
- 2009-01-14 WO PCT/EP2009/050387 patent/WO2009090190A1/en not_active Ceased
- 2009-01-14 AU AU2009204864A patent/AU2009204864A1/en not_active Abandoned
- 2009-01-14 CA CA2710494A patent/CA2710494A1/en not_active Abandoned
- 2009-01-14 EP EP09702062.2A patent/EP2238252B1/en not_active Not-in-force
- 2009-01-14 JP JP2010541803A patent/JP2011511622A/ja active Pending
-
2010
- 2010-06-20 IL IL206484A patent/IL206484A0/en unknown
- 2010-06-21 ZA ZA2010/04367A patent/ZA201004367B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011501652A5 (https=) | ||
| Giardoglou et al. | On zebrafish disease models and matters of the heart | |
| Alenina et al. | ACE2 in brain physiology and pathophysiology: evidence from transgenic animal models | |
| Schinke et al. | Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen | |
| Lerman et al. | Animal models of hypertension: a scientific statement from the American Heart Association | |
| Kusche-Vihrog et al. | Salt controls endothelial and vascular phenotype | |
| Caravia et al. | The microRNA-29/PGC1α regulatory axis is critical for metabolic control of cardiac function | |
| Dao et al. | Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans | |
| Asselbergs et al. | Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci | |
| Yamada et al. | Promoter decommissioning by the NuRD chromatin remodeling complex triggers synaptic connectivity in the mammalian brain | |
| Fatscher et al. | Mechanism, factors, and physiological role of nonsense-mediated mRNA decay | |
| Tunquist et al. | Loss of AKAP150 perturbs distinct neuronal processes in mice | |
| Kapoor et al. | An enhancer polymorphism at the cardiomyocyte intercalated disc protein NOS1AP locus is a major regulator of the QT interval | |
| Gooz | ADAM-17: the enzyme that does it all | |
| Takaluoma et al. | Tissue-specific changes in the hydroxylysine content and cross-links of collagens and alterations in fibril morphology in lysyl hydroxylase 1 knock-out mice | |
| JP2015523863A5 (https=) | ||
| JP2010516235A5 (https=) | ||
| Duverger et al. | In vivo impact of Dlx3 conditional inactivation in neural crest‐derived craniofacial bones | |
| Ichinose et al. | Development of a highly potent analogue and a long-acting analogue of oxytocin for the treatment of social impairment-like behaviors | |
| AU2019392679A1 (en) | Methods of detecting, preventing, reversing, and treating neurological diseases | |
| O'Callaghan et al. | Central angiotensinergic mechanisms associated with hypertension | |
| Rousselle et al. | (Pro) renin receptor and V-ATPase: from Drosophila to humans | |
| Charton et al. | Removal of the calpain 3 protease reverses the myopathology in a mouse model for titinopathies | |
| JP2011511622A5 (https=) | ||
| TW201038740A (en) | A mouse model for depression, schizophrenia and Alzheimer's disease |